A new study by Harvard economist Rebecca Diamond has linked GLP-1 weight-loss medications, such as Ozempic and Wegovy, to improved social and economic outcomes for some women, including better marriage and employment prospects. The findings suggest that weight loss achieved through these drugs may extend beyond physical health benefits, potentially influencing life outcomes tied to societal attitudes towards body weight, such as hiring decisions and dating success.

Diamond's research drew on data from the Understanding America Study, a long-running US panel survey, to track changes in participants' circumstances following GLP-1 use. While the full scope of the article's findings was not detailed, the study adds to a growing body of research examining the broader social effects of the weight-loss drug boom, alongside their established medical benefits for obesity and related chronic conditions.